A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Start Date
3/9/2026
Completion Date
12/1/2032
Summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Pirtobrutinib
Idelalisib
Conditions
Locations
Mitchell Cancer Institute
Mobile, Alabama 36693
United States
Arizona Oncology Associates, P.C. - HOPE
Tucson, Arizona 85711
United States
Cancer Specialists, LLC
Jacksonville, Florida 32256
United States
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota 55433
United States
Cayuga Cancer Center
Ithaca, New York 14850
United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York 10065-6007
United States
Oncology Hematology Care Inc
Cincinnati, Ohio 45211
United States
Texas Oncology - Paris
Fort Worth, Texas 76104
United States
US Oncology - Texas Oncology
Kyle, Texas 78640
United States
The Alfred Hospital
Melbourne, 3004
Australia
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, 5020
Austria
AZ Delta
Roeselare, 8800
Belgium
Princess Margaret Cancer Centre - University Health Network
Toronto, M5G 2M9
Canada
Xuanwu Hospital Capital Medical University
Beijing, 100053
China
Hunan Cancer Hospital
Changsha, 410013
China
Sun Yat-sen University Cancer Center
Guangdong, 510060
China
Nanfang Hospital of Southern Medical University
Guangzhou, 510515
China
Gansu Provincial Cancer Hospital
Lanzhou, 730050
China
The First Affiliated Hospital of Nanchang University
Nanchang, 330006
China
Fudan University Shanghai Cancer Center
Shanghai, 200032
China
Taizhou Hospital of Zhejiang Province
Taizhou, 317000
China
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, 300020
China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, 300060
China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, 830000
China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, 221000
China
Henan Cancer Hospital
Zhengzhou, 450003
China
University Hospital Center Zagreb
Zagreb, 10000
Croatia
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05
Czechia
Centre Henri Becquerel
Rouen, 76038
France
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
Budapest, 1097
Hungary
Debreceni Egyetem
Debrecen, 4032
Hungary
St. James's Hospital
Dublin, D08 NHY1
Ireland
Beaumont Hospital
Dublin, DUBLIN 9
Ireland
Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo
Alessandria, 15121
Italy
Azienda Ospedaliera Universitaria Careggi
Florence, 50134
Italy
Presidio Ospedaliero Papardo
Messina, 98158
Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, 20900
Italy
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
Perugia, 06129
Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, 00138
Italy
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906
Italy
Azienda Ospedaliera S. Maria Di Terni
Terni, 05100
Italy
Tokai University Hospital
Isehara, 259-1193
Japan
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
Brzozów, 36-200
Poland
Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy
Bydgoszcz, 85-168
Poland
Pratia Onkologia Katowice
Katowice, 40-519
Poland
Hospital Universitario Marques De Valdecilla
Santander, 39008
Spain
Hospital Universitario Virgen Del Rocio
Seville, 41010
Spain
Castle Hill Hospital
Hull, HU16 5JQ
United Kingdom
St James's University Hospital
Leeds, LS9 7TF
United Kingdom
GenesisCare
Newmarket, CB8 7XN
United Kingdom